Study Design Powered by AI and Data from Advarra’s IRB and Clinical Trial Systems
Simplify Trial Designs to Improve Operational Efficiency in Clinical Trials
Clinical trial protocol optimization processes are often done with incomplete data, using in-house studies or public datasets. This leaves researchers without robust comparative intelligence to improve trial designs and downstream operational efficiency.
Advarra Study Design solution provides insights on design factors that drive operational feasibility, such as the impact of eligibility criteria, burdensomeness of the schedule of assessment on sites and participants, and reasons for amendments. These insights enable sponsors to better anticipate downstream operational challenges, make informed decisions on how to simplify trial designs, and accelerate protocol development timelines.
Process Improvement
Accelerate the study design process with fewer and smoother iterations.
Simpler Designs
Minimize study operational complexity to accelerate trial timelines.
Competitive Edge
Ground protocol design decisions in unmatched operational intelligence for a competitive edge.
Study Design solution is powered by Braid™, Advarra’s data and AI engine
Braid includes a uniquely rich and comprehensive set of operational data drawn from Advarra’s institutional review board (IRB) and clinical trial systems, encompassing over 170,000 protocol-related documents and operations data from 30,000 studies across over 3,500 sponsors.
Braid transforms unstructured data into actionable intelligence—enabling smarter trial design, faster decisions, and streamlined execution across the clinical trial lifecycle.
Featured Content
Press Release
Advarra launches AI- and Data-Backed Study Design Solution to Improve Operational Efficiency in Clinical Trials
Read the full announcement to learn more about the launch of Advarra’s Study Design solution.
Video Clip
Weaving Intelligence into Clinical Trials
Explore how data, AI, and simulation can transform the way trials are designed—reducing amendments, improving efficiency, and aligning study planning with operational realities.
Blog
Advarra’s Perspective on FDA’s Draft AI Guidance: Advancing Responsible Innovation
Advarra’s Laura Russell, SVP and head of data and AI product development, shares Advarra’s perspective on the FDA’s recent AI guidance—grounded in scientific rigor and implementation experience—highlighting five key areas for potential evolution.